原著論文（査読付き英文および和文）（本HPに関係するものを抜粋）、 　　2023.10.31.更新

  1. Y Chisaki, H. Nakano, J. Minamide, Y. Yano. Cost-Effectiveness Analysis of Atezolizumab versus Platinum-Based Chemotherapy as First-Line Treatment for Patients with Unresectable Advanced Non-small Cell Lung Cancer with PD-L1 Expression Status in Japan. Clin. Drug Investig,, 43(11): 839-850 (2023).
  2. C. Matsumura, N. Koyama, K. Okuno, N. Nakamura, M. Sako, H. Kurosawa, T. Nomura, Y. Eguchi, K. Ohba, Y. Yano. Survival prediction of patients who were terminally ill using the EORTC QLQ-C15-PAL scores and laboratory test values. Palliat. Med. Reports, 4(1): 202-207 (2023).
  3. H. Hata, C. Matsumura, Y. Chisaki, K. Nishioka, M. Tokuda, K. Miyagi, T. Suizu, Y. Yano. A retrospective cohort study of multiple immune-related adverse events and clinical outcomes among patients with cancer. Cancer Control, 29: (2022).
  4. N. Koyama, C. Matsumura, Y. Tahara, M. Sako, H. Kurosawa, T. Nomura, Y. Eguchi, K. Ohba, Y. Yano. Symptom clusters and their influence on prognosis using EORTC QLQ-C15-PAL scores in terminally ill patients with cancer. Support. Care Cancer, 30(1): 135-143 (2022).
  5. Y. Chisaki, H. Hata, C. Matsumura, Y. Yano. The occurrence of encephalitis due to immune checkpoint inhibitors: A pharmacovigilance study. Ther. Innov. Regul. Sci., 56(2): 323-332 (2022).
  6. N. Koyama, C. Matsumura, Y. Shitashimizu, M. Sako, H. Kurosawa, T. Nomura, Y. Eguchi, K. Ohba, Y. Yano. The role of EORTC QLQ-C15-PAL scores and inflammatory biomarkers in predicting survival in terminally ill patients with cancer. BMC Cancer, 21(1): 304 (2021).
  7. C. Matsumura, N. Koyama, M. Sako, H. Kurosawa, T. Nomura, Y. Eguchi, K. Ohba, Y. Yano. Comparison of patient self-reported quality of life and healthcare professional-assessed symptoms in terminally ill patients with cancer. Am. J. Hosp. Palliat. Med., 38(3): 283-290 (2021).
  8. C. Matsumura, M. Yamada, Y. Jimaru, R. Ueno, K. Takahashi, Y. Yano. Relationship between pain scores and EORTC QLQ-C15-PAL scores in outpatients with cancer pain receiving opioid therapy. Biol. Pharm. Bull., 44(3): 357-362 (2021).
  9. 今西孝至、岩竹柚樹、岡村美代子、矢野義孝、楠本正明.　在宅医療における薬剤師の役割に対する訪問看護師の意識調査 －テキストマイニングによる客観的解析－．医療薬学，47(1): 25-32 (2021)．
  10. Y. Chisaki, Y. Kuwada, C. Matsumura, Y Yano. Cost-effectiveness analysis of atezolizumab plus nab-paclitazel for PD-L1 positive triple-negative center in Japan. Clin. Drug Investig., 41(4): 381-389 (2021).
  11. H. Hata, T. Mio, D. Yamashita, C. Matsumura, Y. Chisaki, H. Motohashi, Y. Yano. Factors associated with efficacy and nivolumab-related interstitial pneumonia in non-small cell lung cancer: A retrospective survey. Cancer Control., 27(4): (2020).
  12. M. Yamada, C. Matsumura, Y. Jimaru, R. Ueno, S. Torii, K. Takahashi, Y. Yano. Effect of chemotherapy and predictive factors for nausea or vomiting in patients with cancer receiving opioid analgesics for the first time (オピオイド鎮痛薬導入時の悪心・嘔吐の予測因子の探索と化学療法の影響)．Palliat. Care Res., 15(3): 213-220 (2020).
  13. T. Ishida, M.S. Khan, H. Kodama, Y. Uejima, Y. Kawase, T. Matsumoto, Y. Yamamura, N. Sera, T. Goto, M. Hirakawa, Y. Yano, M. Shima, N. Yamagishi, K. Wakabayashi, T. Watanabe. Association of protein and endotoxin in outdoor air with emergency department visits for children and adults with asthma in Fukuoka, Japan. Biol. Pharm. Bull., 43(9): 1361-1366 (2020).
  14. M.S. Khan, S. Coulibaly, T. Matsumoto, Y. Yano, M. Miura, Y. Nagasaka, M. Shima, N. Yamagishi, K. Wakabayashi, T. Watanabe. Association of airborne particles, protein, and endotoxin with emergency department visits for asthma in Kyoto, Japan. Environmental Health and Preventive Medicine, 23(1): 41 (2018).
  15. 地嵜悠吾、堀口大介、松村千佳子、矢野義孝．医薬品副作用データベースにおける情報抽出と解析の自動化を目的としたアプリケーションの開発．日本病院薬剤師会雑誌，54(11), 1384-1390 (2018).
  16. M. Yamada, C. Matsumura, Y. Jimaru, R. Ueno, K. Takahashi, Y. Yano. Effect of continuous pharmacist interventions on pain control and side effect management in outpatients with cancer receiving opioid treatments. Biol. Pharm. Bull., 41(6): 858-863 (2018).
  17. C. Matsumura, Y. Chisaki, S. Sakimoto, H. Sakae, Y. Yano. Evaluation of thromboembolic events in cancer patients receiving bevacizumab according to the Japanese Adverse Drug Event Report database. J. Oncol. Pharm. Practice, 24(1): 22-27 (2018).
  18. Y. Kimura, Y. Chisaki, T. Saki, C. Matsumura, H. Motohashi, M. Onoue, Y. Yano. Prediction of apparent oral clearance of small-molecule inhibitors in pediatric patients. J. Pharm. Sci., 107(3): 949-956 (2018).
  19. Y. Chisaki, S. Aoji, Y. Yano. Analysis of adverse drug reaction risk in elderly patients using the Japanese Adverse Drug Event Report (JADER) database. Biol. Pharm. Bull., 40(6): 73-81 (2017).
  20. N. Koyama, C. Matsumura, H. Morii, C. Hasegawa, D. Hira, Y. Daigo, T. Terada, Y. Yano. Investigation of optimal time for starting betamethasone using fatigue scores and prognostic nutritional index in terminally ill patients with cancer-related fatigue. Am. J. Hosp. Palliat. Med., 34(5): 449-455 (2017).
  21. Y. Chisaki, N. Nakamura, Y. Yano. Time-series modeling and simulation for comparative cost-effective analysis in cancer chemotherapy; an application to platinum-based regimens for advanced non-small cell lung cancer. Biol. Pharm. Bull. 40(1): 73-81 (2017).
  22. Y. Chisaki, T. Terada, Y. Yano. Population pharmacodynamic model for Bayesian prediction of myelosuppression profiles based on routine clinical data after gemcitabine and carboplatin treatment. Pharmacology, 98(5-6): 284-293 (2016).
  23. A. Takada, M. Katashima, A. Kaibara, K. Chono, K. Katsumata, T. Sawamoto, H. Suzuki, Y. Yano. Integrative pharmacokinetic-pharmacodynamic modeling and simulation of amenamevir (ASP2151) for treatment of recurrent genital herpes. Drug Metab. Pharmacokinet. 31(4): 323-332 (2016).
  24. Y. Ohata, Y. Tomita, K. Suzuki, T. Maniwa, Y. Yano, Keisuke Sunakawa. Pharmacokinetic evaluation of liposomal amphotericin B (L-AMB) in patients with invasive fungal infection: population approach in Japanese pediatrics Drug Metabolism and Pharmacokinetics. Drug Metab. Pharmacokinet., 30(6): 400-409 (2015).
  25. D. Hira, Y. Chisaki, S. Noda, H. Araki, T. Uzu, H. Maegawa, Y. Yano, S. Morita, T. Terada. Population pharmacokinetics and therapeutic efficacy of febuxostat in patients with severe renal impairment. Pharmacol., 96(1-2): 90-98 (2015).
  26. C. Matsumura, M. Yamada, S. Fujihara, Y. Chisaki, K. Takahashi, Y. Yano. Indication of adequate transdermal fentanyl dose in opioid switching from oral oxycodone in patients with cancer. Am. J. Hosp. and Palliat. Med., 33(2): 109-114 (2014).
  27. 山田正実、松村千佳子、地丸裕美、上野理恵、矢野義孝、高橋一栄．外来がん疼痛患者におけるオピオイド鎮痛薬導入に対する薬剤師介入の効果に関する検討．Palliative Care Res., 9(3): 151-157 (2014).
  28. Y. Chisaki, S. Noda, D. Hira, S. Morita, Y. Yano, T. Terada. Reduction in gastrointestinal toxicity by gastric secretion inhibitors during S-1 monotherapy for patients with gastric cancer. Biol. Pharm. Bull., 37(7): 1158-1161 (2014).
  29. T. Kodawara, S. Masuda, Y. Yano, K. Matsubara, T. Nakamura, M. Masada. Inhibitory effect of ciprofloxacin on β-glucuronidase-mediated deconjugation of mycophenolic acid glucuronide. Biopharm. Drug Disp., 35(5): 275-283 (2014).
  30. T. Katsube, T. Wajima, Y. Yamano, Y. Yano. Pharmacokinetic / pharmacodynamic modeling for concentration-dependent bactericidal activity of a bicyclolide, modithromycin. J. Pharm. Sci. 103(4): 1288-1297 (2014).
  31. 正法院友理奈、松村千佳子、中村暢彦、森 由美子、田崎武信、矢野義孝．適切な鎮痛薬選択のためのがん患者が訴える痛みの表現語とオピオイドの効果との相関性評価．Palliative Care Res., 8(2): 376-387 (2013).
  32. C. Matsumura, N. Nakamura, Y. Aomatsu, H. Kuwata, A. Takayama, Y. Yano. Need for pharmaceutical care during chemotherapy for prevention of side effects: examples of blood sugar monitoring in dexamethasone treatment, Palliative Care Res. 7(1): 101-111 (2012).
  33. 山田正実，松村千佳子，杉本更絵子，高橋一栄：貼付型フェンタニル3日製剤から1日製剤に切り替えた際のアンケート調査報告．日本病院薬剤師会雑誌, 48(10): 1213-1216 (2012).
  34. 濱武清範、中村暢彦、松村千佳子、矢野義孝．QRコードを利用したがん化学療法おける情報伝達手法の構築．医療薬学，38(7): 435-440 (2012).
  35. 林 淳雄，中村暢彦，松村千佳子，平井三保子，籠本基成，石津雅弘．ペメトレキセド投与時の皮疹発現リスク軽減要因の検討．日本病院薬剤師会雑誌，48(7): 845-848 (2012).
  36. 地嵜悠吾, 中村暢彦, 松村千佳子, 矢野義孝．ステロイド軟膏製剤の塗布量に関する新規基準の提案．医療薬学，37(11): 637-642 (2011).
  37. Y. Kubota, Y. Yano, S. Seki, K. Takada, M. Sakuma, T. Morimoto, A. Akaike, A. Hiraide. Assessment of pharmacy students’ communication competence using the Roter interaction analysis system during objective structured clinical examinations., Am. J. Pharm. Educ., 75(3): Article 43 (2011).
  38. 窪田愛恵，矢野義孝，関 進，高田香織，佐久間未織，森本 剛，平出 敦．薬学OSCEにおける情報収集能力の評価に関する検討．医学教育，41(4): 273-279 (2010).　
  39. T. Katsube, Y. Yano, T. Wajima, Y. Yamano, M. Takano, Pharmacokinetic / pharmacodynamic modeling and simulation to determine effective dosage regimens for doripenem. J. Pharm. Sci., 99(5): 2483-2491 (2010).
  40. S. Takemoto, K. Yamaoka, M. Nishikawa, Y. Yano and Y. Takakura, Bootstrap method-based estimation of the minimum sample number for obtaining pharmacokinetic parameters in preclinical experiments. J. Pharm. Sci., 99(4): 2176-2184 (2010).
  41. 松村千佳子，倉田義昭，柳田佐江子，中村暢彦，青松幸雄，小林経宏，桑田博文：がん化学療法患者の糖尿病発症についての検討．日本病院薬剤師会雑誌，45(9): 1209-1212 (2009).
  42. Y. Yano, T. Kodawara, H. Hongo, I. Yano, Y. Kishi, J. Takahashi, K. Inui. Population analysis of myelosuppression profiles using routine clinical data after the ICE (ifosfamide / carboplatin / etoposide) regimen for malignant gliomas. J. Pharm. Sci., 98(11): 4402-4412 (2009).
  43. 窪田愛恵，矢野義孝，森本 剛，関 進，高田香織，蔵本伸生，前田祐子，赤池昭紀，平出 敦．薬学OSCEにおけるコミュニケーション能力評価の信頼性に関する検討．薬学雑誌，129(5): 609-616 (2009).
  44. S. Omote, Y. Yano, T. Hashida, S. Masuda, I. Yano, T. Katsura and K. Inui. A retrospective analysis of vancomycin pharmacokinetics in Japanese cancer and non-cancer patients based on routine trough monitoring data. Biol. Pharm. Bull., 32(1): 99-104 (2009).
  45. T. Katsube, Y. Yano, Y. Yamano, T. Munekage, N. Kuroda and M. Takano. Pharmacokinetic-pharmacodynamic modeling and simulation for bactericidal effect in an in vitro dynamic model. J. Pharm. Sci., 97(9): 4108-4117 (2008).
  46. T. Katsube, Y. Yamano and Y. Yano. Pharmacokinetic-pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model. J. Pharm. Sci., 97(4): 1606-1614 (2008).
  47. 窪田愛恵，矢野義孝，森本 剛，高田香織，蔵本伸生，関 進，前田祐子，赤池昭紀，平出 敦．薬学OSCEでの患者応対課題における評価方法に関する検討．医療薬学，34(11): 1004-1010 (2008).
  48. K. Shimamura, T. Wajima, Y. Yano. Pharmacokinetic prediction for intravenous beta-lactam antibiotics in pediatric patients. J. Pharm. Sci., 96(11): 3125-3139 (2007).
  49. 砂川慶介，西村忠史，本廣 孝，岩井直一，矢野義孝，輪嶋恵宏，藤井良知．小児感染症患者における cefcapene pivoxil 小児用細粒の有効性，安全性および薬物動態の検討．日本化学療法学会誌，54(5): 465-477 (2006).
  50. A. Ohnishi, Y. Yano, T. Ishibashi, T. Katsube, T. Oguma. Evaluation of Bayesian predictability of vancomycin concentration using population pharmacokinetic parameters in pediatric patients. Drug Metab. Pharmacokinet., 20(6): 415-422 (2005).
  51. T. Ishibashi, K. Fukumura, Y. Yano, T. Oguma. Determination of optimal dosage for nedaplatin based on pharmacokinetic and toxicodynamic analysis. Anticancer Res., 25(2): 1273-1282 (2005).
  52. T. Ishibashi, K. Fukumura, Y. Yano, T. Oguma. Optimal sampling and limited sampling strategies for estimation of unbound platinum AUC after nedaplatin infusion. Anticancer Res., 25(2): 1283-1290 (2005).
  53. T. Wajima, Y. Yano, K. Fukumura, T. Oguma. Prediction of human pharmacokinetic profile in animal scale up based on normalizing time course profiles. J. Pharm. Sci., 93(7): 1890-1900 (2004).
  54. T. Ishibashi, Y. Yano, T. Oguma. Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients. Br. J. Clin. Pharmacol., 56(2): 205-213 (2003).
  55. T. Wajima, K. Fukumura, Y. Yano, T. Oguma. Prediction of human pharmacokinetics from animal data and molecular structural parameters using multivariate regression analysis: oral clearance. J. Pharm. Sci., 92(12): 2427-2440 (2003).
  56. T. Wajima, K. Fukumura, Y. Yano, T. Oguma. Prediction of human pharmacokinetics from animal data and molecular structural parameters using multivariate regression analysis: volume of distribution at steady state. J. Pharm. Pharmacol., 55(7): 939-949 (2003).
  57. T. Wajima, K. Fukumura, Y. Yano, T. Oguma. Prediction of human clearance from animal data and molecular structural parameters using multivariate regression analysis. J. Pharm. Sci., 91(12): 2489-2499 (2002).
  58. T. Ishibashi, Y. Yano, T. Oguma. A formula for predicting optimal dosage of nedaplatin based on renal function in adult cancer patients. Cancer Chemother. Pharmacol., 50: 230 -236 (2002).
  59. T. Wajima, Y. Yano, T. Oguma. A pharmacokinetic model for analysis of drug disposition profiles undergoing enterohepatic circulation. J. Pharm. Pharmacol., 54(7): 929-934 (2002).
  60. A. Ohnishi, Y. Yano, K. Shimamura, T. Oguma. Evaluation of Bayesian predictability of vancomycin concentration in patients with various degrees of renal function. Biol. Pharm. Bull., 24(12): 1446-1450 (2001).
  61. Y. Yano, S.L. Beal, L.B. Sheiner. Evaluating pharmacokinetic / pharmacodynamic models using the posterior predictive check. J. Pharmacokinet. Pharmacodyn., 28(2): 171-192 (2001).
  62. T. Ishibashi, Y. Yano, T. Oguma. Pharmacodynamics of S-2150, a simultaneous calcium-blocking and 1-inhibiting antihypertensive drug, in rats. J. Pharm. Pharmacol., 52(3): 273-280 (2000).
  63. Y. Yano, T. Oguma, H. Nagata, S. Sasaki. Application of logistic growth model to pharmacodynamic analysis of in vitro bactericidal kinetics. J. Pharm. Sci., 87(10): 1177-1183 (1998).
  64. M. Yasuhara, T. Iga, K. Okumura, H. Zenda, T. Oguma, Y. Yano, R. Hori. Population pharmacokinetics of vancomycin in Japanese pediatric patients. Ther. Drug Monit., 20(6): 612-618 (1998).
  65. M. Yasuhara, T. Iga, K. Okumura, H. Zenda, T. Oguma, Y. Yano, R. Hori. Population pharmacokinetics of vancomycin in Japanese adult patients. Ther. Drug Monit., 20(2): 139-148 (1998).
  66. 尾熊隆嘉，矢野義孝，財前政美，牡丹義弘，伊賀立二，全田 浩，奥村勝彦，安原眞人，堀 了平．Vancomycinの有効性，安全性に関与する要因の統計解析．日本化学療法学会雑誌，45(12): 987-994 (1997).
  67. 矢野義孝，尾熊隆嘉，安原眞人，伊賀立二，全田 浩，奥村勝彦，掘 了平．バンコマイシン TDM における母集団薬物速度論的解析と評価．TDM研究，14(3): 231-236 (1997).
  68. 矢野義孝，尾熊隆嘉．Visual Basicによるベイジアン法に基づくTDM支援のための体内動態解析ソフトウェアの開発．TDM研究，14(2): 159-168 (1997).
  69. Y. Yano, A. Hiraoka, T. Oguma. Enhancement of tobramycin binding to rat renal brush border membrane by vancomycin. J. Pharmacol. Exp. Ther., 274(2): 695-699 (1995).
  70. Y. Yano, K. Yamaoka, H. Yasui, T. Nakagawa. Effect of perfusion rate on the local disposition of cefixime in liver perfusion system based on two-compartment dispersion model. Drug Metab. Dispos., 19(6): 1022-1027 (1991).
  71. Y. Yano, K. Yamaoka, H. Yasui, T. Nakagawa. Analysis of arterial-venous blood concentration difference of drugs based on recirculatory theory with Fast Inverse Laplace Transform (FILT). J. Pharmacokinet. Biopharm., 19(1): 71-85 (1991).
  72. K. Yamaoka, M. Kanba, Y. Toyoda, Y. Yano, T. Nakagawa. Analysis of enterohepatic circulation of cefixime in rat by Fast Inverse Laplace Transform (FILT). J. Pharmacokinet. Biopharm., 18(6): 545-559 (1990).
  73. Y. Yano, K. Yamaoka, T. Minamide, T. Nakagawa, H. Tanaka. Evaluation of protein binding effect on local disposition of oxacillin in rat liver by a two-compartment dispersion model. J. Pharm. Pharmacol., 42(9): 632-636 (1990).
  74. Y. Yano, K. Yamaoka, H. Tanaka. A nonlinear least squares program, MULTI(FILT), based on Fast Inverse Laplace Transform for microcomputers. Chem. Pharm. Bull., 37(4): 1035-1038 (1989).
  75. Y. Yano, K. Yamaoka, Y. Aoyama, H. Tanaka. Two-compartment dispersion model for analysis of organ perfusion system of drugs by Fast Inverse Laplace Transform (FILT). J. Pharmacokinet. Biopharm., 17(2): 179-202 (1989).
  76. K. Yamaoka, Y. Yano, O. Sakurai, H. Tanaka, Effect of probenecid on disposition of cefpiramide in rat. The application of population pharmacokinetics. Chem. Pharm. Bull., 35(3): 1196-1200 (1987).
  77. Y. Yano, K. Yamaoka, H. Tanaka. An automated dissolution measurement program for microcomputers. Chem. Pharm. Bull., 34(7): 2963-2966 (1986).